Shionogi, established in 1878, is dedicated to developing innovative treatments for global health challenges such as antimicrobial resistance and COVID-19. With a history of introducing novel antibiotics and advanced medications for HIV and influenza, the company continues to advance clinical programs in areas like Fragile X syndrome, acute ischemic stroke, metabolic disorders, and oncology. Driven by a commitment to patient impact, Shionogi fosters strategic partnerships with industry leaders to accelerate scientific advancements and deliver first-in-class therapies worldwide.
The Senior Director, Global Epidemiology & Real-World Evidence (RWE) sets and drives the U.S. RWE strategy across therapeutic areas while ensuring alignment with global vision. The role provides leadership to global epidemiology staff and plays a critical role in shaping organizational-level RWE standards, innovation, and external influence.
Shionogi, established in 1878, is dedicated to developing innovative treatments for global health challenges such as antimicrobial resistance and COVID-19. With a history of introducing novel antibiotics and advanced medications for HIV and influenza, the company continues to advance clinical programs in areas like Fragile X syndrome, acute ischemic stroke, metabolic disorders, and oncology. Driven by a commitment to patient impact, Shionogi fosters strategic partnerships with industry leaders to accelerate scientific advancements and deliver first-in-class therapies worldwide.
Eikon Therapeutics